Introduction {#s1}
============

Gitelman syndrome (GS) is a rare autosomal-recessive inherited disorder with 99% penetrance caused by inactivating mutations in the SLC12A3 gene, localized on the 16q13 chromosome. This genetic defect impairs the function of the thiazide-sensitive sodium-chloride cotransporter in the distal convoluted renal tubule. GS is the hypocalciuric, hypomagnesemic variant of Bartter syndrome, which was first described in 1966 \[[@SFS126C1]\]. The impact of this condition on maternal and fetal outcome is still unclear. Here, we describe the management and pregnancy course of a 27-year-old patient with GS.

Case presentation {#s2}
=================

We report the course of a pregnancy in a 27-year-old woman previously diagnosed with GS. Her pregnancy was uneventful and she remained asymptomatic despite persistent hypokalemia. Potassium levels were followed at a regular basis and ranged between 2.3 and 3.1 mmol/L (2.3 and 3.1 mEq/L). She was electively admitted to hospital at 39 weeks of gestational age for full-term induction of labor. A PICC line was placed to allow replacement of electrolytes. The patient received 240 mEq of intravenous potassium chloride and 180 mEq per oral, as well as 4 g of intravenous magnesium sulfate and 1200 mEq of oral magnesium oxide. She was continued on 150 mg daily of eplerenone. Despite aggressive electrolyte replacement, her potassium and magnesium levels ranged between 2.0 and 3.0 mmol/L (2.0 and 3.0 mEq/L) and 1.1 and 2.6 mmol/L (1.1 and 2.6 mEq/L), respectively. The baby was born healthy with 2863 g, and Apgar measurements were 8 and 9 at 1 and 5 min, respectively. She was discharged two days after giving birth and has remained symptom free.

Discussion {#s3}
==========

First described in 1966 by Gitelman *et al.*, GS is a rare autosomal-recessive condition characterized by hypokalemia, metabolic alkalosis and hypomagnesemia \[[@SFS126C1]\]. It has since been shown to result from a mutation in the SLC12A3 gene on chromosome 16 leading to a loss of function mutation in the sodium-chloride cotransporter in the distal convoluted tubule. This leads to potassium and magnesium wasting into the cortical collecting duct as the increase in delivered sodium is reabsorbed through the epithelial sodium channel. Despite being normotensive, the patients clinically have activation of the renin--angiotensin--aldosterone axis \[[@SFS126C2]\]. To date, 24 pregnancies in 18 women with GS have been described in the literature \[[@SFS126C3]--[@SFS126C15]\]. Twenty of the pregnancies had no reported fetal complication ([Table 1](#SFS126TB1){ref-type="table"}), six pregnancies were complicated by oligohydramnios \[[@SFS126C5], [@SFS126C8], [@SFS126C9], [@SFS126C12], [@SFS126C13]\] and one was complicated by intrauterine growth retardation \[[@SFS126C8]\]. The management of maternal GS during pregnancy continues to be a challenge. Renin, angiotensin II and aldosterone levels are known to increase during pregnancy \[[@SFS126C16]\]. Kaliuresis does not typically ensue presumably due to the antimineralocorticoid effects of progesterone demonstrated by Ehrlich and Lindheimer in 1972 \[[@SFS126C17]\]. De Haan *et al.* have suggested that this protective mechanism may be impaired in GS patients thus resulting in an exacerbation of potassium and magnesium losses \[[@SFS126C8]\]. Oral potassium and magnesium supplements continue to be the mainstay of therapy. The increase in the requirement for oral potassium during pregnancy has been documented by several authors including Talaulikar *et al.* in 2005 who reported a 6-fold increase in potassium and magnesium requirements in their patient \[[@SFS126C7]\]. Six of the pregnancies document the use of intravenous potassium \[[@SFS126C7]--[@SFS126C12]\]. Intravenous magnesium was required in three cases \[[@SFS126C7]--[@SFS126C9]\]. Two authors report achievement of potassium levels in the 3.6--4 mmol/L (3.6--4.0 mEq/L) range \[[@SFS126C10], [@SFS126C14]\]. The remainder of the documented cases had peak potassium levels ranging from 2.8 to 3.3 mmol/L (2.8--3.3 mEq/L). It has been suggested that normalization of potassium and magnesium levels is not required for a good obstetric and neonatal outcome \[[@SFS126C6]\]. Worsening of the symptoms of GS such as fatigue, cramping, tetany and dizziness has been described in the GS pregnancies \[[@SFS126C7], [@SFS126C12], [@SFS126C13]\]. The symptoms may be exacerbated by hyperemesis and fetal demand for potassium \[[@SFS126C9], [@SFS126C12]\]. Worsening of symptoms is cited as a reason for the modification of therapy \[[@SFS126C3], [@SFS126C4], [@SFS126C6]--[@SFS126C11], [@SFS126C13]\]. Our patient did not exhibit symptoms during her pregnancy, and we felt that intravenous potassium loading would be inefficient and unnecessary in the absence of symptoms. Beyond the use of supplemental cations, the management of patients with GS has included the use of potassium-sparing diuretics. The US Food and Drug Administration has deemed spironolactone a category C drug in pregnancy. De Arriba *et al.* describe the use of spironolactone in one pregnancy \[[@SFS126C12]\]. The authors note that no feminization was seen in the male newborn. This is consistent with the findings of Mascetti *et al.* who describe a series of spironolactone-exposed children born to a group of mothers with Bartter syndrome, another potassium-wasting nephropathy \[[@SFS126C4]\]. The use of amiloride and eplerenone, both class B drugs in pregnancy, has been previously documented in GS \[[@SFS126C4], [@SFS126C9], [@SFS126C14], [@SFS126C15]\]. In contrast to Bartter syndrome, the use of non-steroidal anti-inflammatory drugs (NSAIDs) to inhibit prostaglandin synthase is theoretically of no benefit as GS is not a hyperprostaglandinemic state \[[@SFS126C18]\]. There is a risk of a lack of ductus arteriosus closure with NSAID use. Angiotensin-converting enzyme inhibitors are contraindicated in pregnancy due to teratogenic effects as well as impaired fetal growth. There has been a concern over the potential for a ventricular tachyarrhythmia during pregnancy and childbirth due to hypokalemia. Fortunately, no such complication has been observed in any of the documented GS pregnancies. The extensive work of Calo *et al.* in this area suggests however that the upregulation of the nitric oxide system and vasodilation seen in GS may limit the physiologic response to increased myocardial demand \[[@SFS126C19], [@SFS126C20]\]. It is also suggested in subsequent work that increased angiotensin 1--7 levels seen in GS may be antiarrhythmic at low levels and proarrhythmic at very high levels \[[@SFS126C21]\]. The small number of documented GS pregnancies precludes any rigorously studied recommendations for management in the peripartum period. The anesthesia literature describes a risk of complications in GS patients in the perioperative setting. These include electrocardiographic changes as well as vasodilation, electrolyte imbalance and alkalemia complicating the ventilatory management of the patient \[[@SFS126C22]\]. Uneventful spinal anesthesia for cesarean delivery is also described in the literature \[[@SFS126C23]\]. Given the expected physiologic demands of labor and delivery, it appears that an elective, multidisciplinary approach to the delivery of the child is most prudent. Baseline electrocardiography should be obtained as up to 50% of patients with GS have QT interval prolongation. Cardiac telemetry and central venous access should be considered at the time of delivery. Frequent monitoring of electrolytes is advisable as is blood pressure monitoring given the propensity of GS patients have vasodilation. A drop in serum potassium during labor is not previously described in the literature. The postpartum period is associated with natriuresis; however, this would not explain a drop in potassium during active labor. It may be, however, that the drop in serum potassium observed here is related to a shift in potassium from the extracellular to intracellular space as could be seen in any patient and is not unique to GS. In our patient, we suspect that increased β-adrenergic tone may have played a role. The effects of epinephrine on hypokalemia were described in 1983 by Struthers *et al.* Pretreatment with a thiazide diuretic was associated with a more significant drop in serum potassium during epinephrine loading than that seen in the control group receiving epinephrine alone \[[@SFS126C24]\]. As GS mimics the effects of thiazide diuretics, one could assume a similar effect in these patients. Cellular shift of potassium may also occur because of rising blood glucose concentrations. Table 1.Summary with the cases of Gitelman syndrome during pregnancyAuthorAge at diagnosis (years)DiagnosisMaternal age (years)Number of patientsNumber of pregnanciesSymptomsJones JM *et al.* \[[@SFS126C5]\]351st trimester3512Initially presented with new onset of seizures37N/ABasu A *et al.* \[[@SFS126C6]\]17Before pregnancy1) 24131st- asymptomatic except for tiredness in 3rd trimester2) 252nd- asymptomatic3) 273rd- asymptomaticTalaulikar GS *et al.* \[[@SFS126C7]\]20Before pregnancy1) 22121) Increasing tiredness, muscle cramps. Required 3 hospitalizationsKwan *et al.* \[[@SFS126C10]\]2) 302) Not describedSrinivas SK *et al.* \[[@SFS126C11]\]172nd trimester (17 weeks)1711Nausea, vomiting, proximal lower extremity muscle weakness. VF arrest, seizures, prolonged QTcDe Haan J *et al.* \[[@SFS126C8]\]N/ABefore pregnancy1) 24211st- symptomatic, not specified2) 272nd- muscle weakness, fatigueDe Arriba G *et al.* \[[@SFS126C12]\]18Before: pregnancy3611Limb paresthesias and cramps, myalgiaDaskalakis G *et al.* \[[@SFS126C13]\]201st trimester (10 weeks)2011Tiredness, muscle weakness, decreased muscle strength and tenderness bilaterally in lower extremitiesMcCarthy FP *et al.* \[[@SFS126C9]\]321st trimester (9 weeks)3211Episodic severe fatigue, postural hypotensionRaffi *et al.* \[[@SFS126C14]\]22Before pregnancy2711Not describedMorton A *et al*. \[[@SFS126C15]\]21Before pregnancyN/A11AsymptomaticMascetti L *et al.* \[[@SFS126C4]\]N/AN/A1) 27561, 2, 3, 4) uneventful 5) tiredness and tetanic seizures2) 323) 284) 335) 33/35Calo LA *et al.* \[[@SFS126C3]\]N/ABefore pregnancy3923Intermittent nausea and vomiting Nausea // N/A24Gestational complicationsDeliveryNeonateGestational agePotassium valuesMagnesium valuesTreatmentOligohydramniosInduced vaginal deliveryHealthy male infant. 2509 g37 weeks∼3.2 mEq/L∼1.3 mEq/LK and Mg supplementationOligohydramniosInduced vaginal deliveryHealthy female infant, 2410 g36 weeksN/AN/AK and Mg supplementation1, 2 and 3) None1st- spontaneous labor1st- healthy male infant. 2620 g1st-35 weeks1st- K range = 2.3--2.8 mmol/L1st- Mg range = 0.53--0.58 mmol/L1st- K and Mg supplementation2nd- spontaneous labor2nd- healthy female infant, 2910 g2nd- 38 weeks2nd- maximum level = 3.1 mmol/L2nd- maximum level = 0.56 mmol/L2nd- K and Mg supplementation3rd-spontaneous labor3- healthy female infant. 3480 g3rd- 38 weeks3rd- N/A3rd- N/A3rd-N/A1) NoneNormal deliveryHealthy infant1) N/AK range = 2.3--3.4 mmol/L1 and 2)N/A1 and 2) K and Mg supplementation2) Gestational diabetesElective C-sectionN/A2) 39 weeksN/ANoneUncomplicated vaginal delivery, induced for post-term pregnancyHealthy female infant, 3250 g41 weeks and 4 daysN/AN/AK and Mg supplementation1st-Oligohydramnios, partial placenta previa, intrauterine growth restriction.1st- primary C-section, healthy infantHealthy female infant, 3970 g1 and 2) 38 weeksN/AN/AK and Mg supplementation. 1st case required i.v. supplementation2nd- secondary C-section. healthy infantHealthy male infant, 3845 gOligohydramniosProgrammed C-section, w/o complicationsHealthy infant, 3000 gN/A2.4--2.8 mEq/LN/AK and Mg supplementation, Spironolactone.OligohydramniosElective C-section (breech presentation)Healthy female baby, 3350 g273Maximum level = 3.0 mmol/LMaximum level = 0.68 mmol/LK and Mg supplementationOligohydramniosInduced C-section (failure to progress in the first stage)Healthy female baby, 2940 g266K range = 2.6--3.3 mmol/LMg range = 0.47--0.66 mmol/LK and Mg supplementation, amiloride. Required 39 hospitalizations i.v. supplementation of K and MgFetal macrosomia (patient had gestational diabetes)Induced C-sectionHealthy male baby, 3080 gN/AN/AN/AK and Mg supplementation, amiloride (1st trimester). Required 1 hospitalization for i.v. supplementation of K and Mg.NoneVaginal deliveryHealthy female baby, 3630 g2732.6--2.9 mmol/LN/AEpleronone1, 2, 3, 4 and 5) NoneN/AHealthy male baby. 4080 g40 weeksN/AN/AK and Mg Homeopathy K, amiloride K, Mg None (1st pregnancy) / K (2nd pregnacy)Healthy female baby, 3380 g38 weeksHealthy female baby, 2420 g37 weeksHealthy male baby. 2810 g41 weeksHealthy male baby, 2830 g/\
healthy male baby, 2640 g38 weeks/36 weeks1 and 2) NoneN/AHealthy female baby 2900 gAt termN/AN/A1 and 2) K and Mg supplementationHealthy female baby 3125 g/\
healthy female baby 3400 gAt term/\
At term

In conclusion, the experience of clinicians treating pregnant women with GS is limited but is also being described with more frequency. There is no evidence of significant risk to the fetus but maternal symptoms may worsen during the pregnancy. The management of GS should be focused on the replacement of potassium and magnesium though routine intravenous supplementation and should be reserved for cases of worsened symptoms. Cautious use of adjunctive treatment with potassium-sparing agents should be considered as the potassium requirement may increase significantly during pregnancy. In addition to GS-related potassium and magnesium loss, hypokalemia can be exacerbated by cellular shift as well as extrarenal losses of cations which can affect any patient. No consensus recommendations exist for the perinatal management of the pregnant GS patient but an elective delivery in a setting with appropriate cardiac monitoring and central venous access is prudent as potassium and magnesium aberrations during active labor may be seen.
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